Lv3
370 积分 2023-11-13 加入
Radiation-Triggered Payload Release Enhances Bispecific Antibody Efficacy
2天前
已完结
MET overexpression correlated with prognosis of EGFR-mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study
3天前
已完结
MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies
4天前
已完结
Targeting MET in cancer: rationale and progress
4天前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
11天前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
11天前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
12天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
12天前
已完结
Epidermal growth factor receptors unveiled: a comprehensive survey on mutations, clinical insights of global inhibitors, and emergence of heterocyclic derivatives as EGFR inhibitors
15天前
已完结
Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts
19天前
已完结
皖公网安备34019202002308
